S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Y Uemura has received speaking fees from Eli Lilly Japan K.K. S Tanaka has received lecture fee from Bayer Japan, MSD K.K., Amgen Astellas BioPharma K.K., JMDC Inc. and Research Institute of Healthcare Data Science. He has received consultation fee from Boehringer Ingelheim and Daiichi Sankyo Co., Ltd. He has received outsourcing fee from Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Ministry of Health, Labour and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Novo Nordisk Pharma Ltd. He engaged in a research project of the Japan Agency for Medical Research and Development. Y Takeuchi has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. N Endo has received lecture honoraria from UCB Japan Co., Ltd. and Kyowa Kirin Co., Ltd. and speaker fees from Tsumura & Co. J Takada has received consulting fees and speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Teijin Pharma Ltd., and Kaken Pharmaceutical Co., Ltd. S Ikeda has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co. Ltd., Viatris Inc., and UCB Japan Co., Ltd. J Iwamoto has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., the Public Health Research Foundation, Taisho Pharmaceutical Holdings Co., Ltd., and Towa Pharmaceutical Co., Ltd. N Okimoto has received payments for lectures, including speakers’ bureau fees from Asahi Kasei Pharma Corp., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., and Teijin Pharma Ltd. Sa Tanaka has received lecture fees from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Amgen Inc., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. and research grants from Eli Lilly Inc., Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd